













# HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS

Neysimelia Costa Villela<sup>1\*</sup> , Anita Frisanco Oliveira<sup>1</sup> , Rafaela de Souza Ferreira<sup>1</sup> , Gustavo Zamperlini<sup>2</sup> , Andréia Cristina Fortes Bassani<sup>3</sup> , Mariana Bohns Michalowski<sup>4,5</sup> , Maria Lúcia de Martino Lee<sup>6</sup> 

1. Hospital de Câncer de Barretos  – Barretos (SP), Brazil.
2. Centro Infantil Boldrini  – Campinas (SP), Brazil.
3. Hospital Unimed – Volta Redonda (RJ), Brazil.
4. Hospital de Clínicas de Porto Alegre  – Porto Alegre (RS), Brazil.
5. Universidade Federal do Rio Grande do Sul  – Porto Alegre (RS), Brazil.
6. Beneficência Portuguesa de São Paulo  – São Paulo (SP), Brazil.

\*Corresponding author: [ncvillela@hotmail.com](mailto:ncvillela@hotmail.com)

Section editor: Fernando Barroso Duarte 

Received: Sept. 11, 2025 • Accepted: Oct. 23, 2025

## ABSTRACT

Juvenile myelomonocytic leukemia (JMML) is a rare and distinctive hematologic neoplasm affecting infants and younger children. Hyperactivation of the RAS signaling pathway is a central initiating event in JMML, which also delineates its various genetic and clinical subtypes. While a small percentage of children may achieve spontaneous clinical remission, allogeneic hematopoietic cell transplantation (HCT) remains the only possible cure for most JMML patients. In this article, we reviewed the indications of HCT in JMML. Other myeloproliferative diseases, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are extremely rare in pediatrics and are briefly discussed.

**Keywords:** Leukemia, Myelomonocytic, Juvenile. Hematopoietic Stem Cell Transplantation. Polycythemia Vera. Thrombocythemia, Essential. Primary Myelofibrosis. Child.

## INTRODUCTION

Juvenile myelomonocytic leukemia (JMML) is a rare hematologic neoplasm of infants and younger children. Characterized by the proliferation of granulocytes and monocytes associated with dyspoiesis, JMML is responsible for 3% of all childhood leukemias<sup>1-3</sup>. Mutations in genes of the *RAS-MAPK* pathway (*NRAS*, *KRAS*, *PTPN11*, *NF1*, and *CBL*) are involved in the pathogenesis of almost all patients with JMML, with a well-defined phenotype-genotype association<sup>4-8</sup>. The identification of the mutated gene is currently necessary not only for diagnosis, but also for prognostic definition and therapeutic strategy, since it identifies subgroups of patients with variable clinical characteristics and evolution<sup>8,9</sup>.

Allogeneic hematopoietic cell transplantation (HCT) represents the only possible cure for the vast majority of patients with JMML, in contrast to a smaller percentage of children who survive long-term without HCT and eventually experience spontaneous clinical remissions<sup>6-10</sup>.

No randomized clinical trials have compared pre-HCT therapy *versus* proceeding directly to transplant. While several chemotherapeutic approaches have been evaluated for reducing disease burden prior HCT, to date, no conventional chemotherapy regimen has demonstrated reduced post-HCT relapse incidence<sup>2,6,8,11,12</sup>. Another approach to upfront treatment involves hypomethylating agents. In the last years, several case series describing hematological and molecular responses to azacitidine and decitabine treatment in pediatric patients with JMML have been published<sup>13-17</sup>. The recent phase 2 study of the European Working Group of Myelodysplastic Syndromes in children (EWOG-MDS) demonstrated that azacitidine provides valuable clinical benefit to JMML patients prior to HCT<sup>18</sup>.

## HEMATOPOIETIC CELL TRANSPLANTATION INDICATIONS IN JUVENILE MYELOMONOCYTIC LEUKEMIA

Patients harboring somatic PTPN11 mutation generally have the highest risk of rapid progression and early death without HCT. Similarly, JMML is also fatal in the absence of HCT in patients with neurofibromatosis type 1 (NF1). Children with somatic KRAS mutation generally exhibit highly aggressive disease manifestations, requiring prompt treatment. However, they respond particularly well to low-dose azacitidine, often achieving sustained clinical and molecular remissions and possibly cure without HCT in those patients with a low-risk profile.

JMML associated with somatic NRAS mutation displays considerable clinical heterogeneity: some patients experience spontaneous disease regression without HCT, while others have an aggressive disease, with a high rate of relapse after HCT (usually older children, with high-fetal hemoglobin levels). Most children with CBL germline mutation present with a self-resolving disease, and observation without therapy is generally recommended, but recent studies reported acquired somatic CBL mutations in some patients showing more aggressive disease and heterogeneous disease course even among patients with germline CBL mutations. For patients presenting with a JMML phenotype but no detectable RAS pathway mutation, HCT is recommended. However, it is essential to exclude other rare myeloproliferative disorders, acute leukemias and non-malignant diseases<sup>6-10,19-22</sup>. HCT indications according to driver mutation are described in Table 1.

**Table 1.** Indications for hematopoietic cell transplantation (HCT) in juvenile myelomonocytic leukemia.

Ras pathway mutation	Allogeneic HCT indication
Somatic PTPN11	Swift HCT
Germline NF1	Swift HCT
Somatic KRAS	Azacitidine and/or HCT
Somatic NRAS	HCT for many, careful selection of candidates for watch-and-wait.
Germline CBL	Watch-and-wait. HCT if disease progression.
All negative	Most patients require HCT

Source: Mayerhofer *et al.*, 2021.

## DONOR SELECTION, CONDITIONING REGIMEN, AND GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS

In more recent years, using a human leukocyte antigen (HLA) matched/1-antigen-disparate unrelated donor (MUD) offers minimal or no significant disadvantage compared with a matched sibling donor (MSD) for HCT in JMML<sup>23-25</sup>. Available data also indicate that umbilical cord blood (UCB) transplantation is a suitable option for children with JMML lacking an HLA-compatible relative<sup>26</sup>. Although there are only a few reports available to date regarding haploidentical HCT for JMML, it can be considered for those patients who lack an HLA-matched donor or need an urgent allograft<sup>27-29</sup>.

The EWOG-MDS and the European Society for Blood and Marrow Transplantation (EBMT) recommend busulfan (BU) + cyclophosphamide (CY) + melphalan (MEL) as the standard conditioning regimen for patients with JMML, resulting in a four-year overall survival (OS), event-free survival (EFS), relapse, and transplant-related mortality (TRM) rates of 64, 52, 35, and 13%, respectively<sup>23</sup>.

A recent prospective clinical study from the Japan Pediatric Leukemia/Lymphoma Study Group demonstrated that the BU + fludarabine (FLU) + MEL regimen may provide similar survival outcomes as BU + CY + MEL, resulting in a three-year OS, EFS, relapse, and TRM rates of 63, 52, 18, and 21%, respectively<sup>24</sup>. In an attempt to reduce toxicity, a prospective randomized trial from the Children's Oncology Group study compared BU/CY/MEL with BU/FLU alone, but terminated early due to the excessive disease recurrence in the latter arm<sup>30</sup>. HCT conditioning regimens recommendations for JMML are described in Table 2.

**Table 2.** Conditioning regimens recommendations in juvenile myelomonocytic leukemia.

Standard: busulfan + cyclophosphamide + melphalan	Busulfan (dose according to body weight* or adjustment based on pharmacokinetic studies <sup>†</sup> , if available): D-8 to D-5 Cyclophosphamide 60 mg/kg/day + Mesna (150% of cyclophosphamide dose): D-4 and D-3 (starting 24 h after busulfan) Melphalan 140 mg/m <sup>2</sup> /day: D-2
Alternative: busulfan + fludarabine + melphalan	Busulfan (dose according to body weight* or adjustment based on pharmacokinetic studies <sup>†</sup> , if available): D-7 to D-4 Fludarabine 30 mg/m <sup>2</sup> /day: D-7 to D-3 Melphalan 140 mg/m <sup>2</sup> /day: D-2

\*IV daily dose = < 9 kg: 4 mg/kg; 9 to < 16 kg: 4.8 mg/kg; 16–23 kg: 4.4 mg/kg; > 23 to 34 kg: 3.8 mg/kg; > 34 kg: 3.2 mg/kg; <sup>†</sup>target AUC 4,000–5,000 µMol·min.  
Source: Elaborated by the authors.

The most frequently employed protocols for graft-versus-host disease (GVHD) prophylaxis in HCT for JMML consist of cyclosporine in MSD HCT and calcineurin inhibitors combined with methotrexate and anti-thymocyte globulin (ATG) in MUD HCT<sup>23,31</sup>. Although incorporating ATG into GVHD prophylaxis sparked concerns about potentially reducing the graft-versus-leukemia (GVL) effect, its administration did not lead to higher relapse rates in children with JMML undergoing MUD transplantation<sup>23,26</sup>. However, studies have shown a lower incidence of disease recurrence after HCT associated with the presence of GVHD in children with JMML, suggesting the existence of a GVL effect directed against JMML cells with subsequent protection against relapse<sup>25,26,32</sup>. In view of these considerations, the EWO-MDS recommends keeping immunosuppressive therapy with cyclosporine A at low levels and tapering early. Children carrying K-RAS mutations can be an exception to this recommendation, as in their experience, they have a lower relapse rate than children with other molecular abnormalities<sup>26</sup>. General GVHD prophylaxis recommendations for JMML patients are described in Table 3.

**Table 3.** Graft-versus-host disease prophylaxis recommendations in juvenile myelomonocytic leukemia.

Matched sibling donor	Cyclosporine as a single agent
Unrelated donor*	Calcineurin inhibitors (cyclosporine or tacrolimus) combined with short methotrexate (D +1, +3 and +6).
Umbilical cord blood*	Calcineurin inhibitors (cyclosporine or tacrolimus) combined with mycophenolate mofetil

\*Anti-thymocyte globulin (ATG) during conditioning regimen for *in-vivo* T-cell depletion/modulation. Source: Elaborated by the authors.

## PREVENTION AND MANAGEMENT OF POST-HEMATOPOIETIC CELL TRANSPLANTATION DISEASE RELAPSE

Relapse remains the leading cause of treatment failure following HCT in JMML, occurring in 30–50% of patients. It generally occurs within the first two years after HCT, with a peak at a median time of two–six months<sup>23,33–35</sup>. Rigorous and regular post-HCT monitoring of donor-recipient chimerism serves as a valuable tool for identifying JMML patients at risk of a forthcoming relapse. In such cases, prompt withdrawal of immunosuppression can prevent disease progression<sup>36,37</sup>.

Age at diagnosis  $\geq$  2 years old, NF1 or somatic PTPN11 mutation, and high DNA methylation define a patient group whose risk of JMML recurrence after HCT is even higher than 50%, bringing up the question of post-transplant prophylaxis. In these cases, some authors suggest considering the use of azacitidine + donor lymphocyte infusions, although emphasizing that there are no systematic data for this approach in JMML<sup>8,9</sup>.

For children with JMML who have overt leukemia relapse after HCT, a second allograft with a low-intensity GVHD prophylaxis can be an effective salvage therapy for at least one-third of patients<sup>2,23,33,34</sup>. Targeted therapies are currently under investigation for patients with relapsed/refractory JMML<sup>38</sup>.

## MYELOPROLIFERATIVE NEOPLASMS

Beyond chronic myeloid leukemia BCR-ABL1+, classic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These conditions exhibit extremely low occurrence rates in pediatric population, with about 0.82 cases for every 100 thousand patients, about 100 times less than in adults. Consequently, understanding of clinical manifestations, molecular profiles, disease outcomes, and optimal therapeutic approaches remains limited for pediatric cases<sup>39-41</sup>.

Pediatric patients typically exhibit a reduced frequency of mutations commonly found in adults, thrombotic events, and transformation to secondary myelofibrosis and acute leukemia<sup>39-41</sup>. Furthermore, well-defined prognostic criteria and corresponding treatment guidelines, including specific indications for allogeneic HCT, remain limited for pediatric patients<sup>41-43</sup>.

Most pediatric patients with PV and ET are treated with supportive care and sometimes cytoreductive therapies<sup>44,45</sup>. In adults, PMF and post-ET/PV myelofibrosis are BCR-ABL1-negative MPNs with the worst survival rates, but allogeneic HCT offers curative potential for many patients. Among children and adolescents, myelofibrosis (MF) is the rarest type of MPNs, and data regarding HCT outcomes in this group remain limited.

Recently, a retrospective study of the EBMT evaluated 35 children with MF, including 33 with primary myelofibrosis and two with secondary myelofibrosis transplanted from MSD, MUD, or UCB. Conditioning was usually chemotherapy-based (busulfan-based in 68.6%) and myeloablative. Six-year non-relapse mortality (NRM) was 18%, relapse incidence was 15.9%, progression-free survival (PFS) was 66.1%, and OS was 71.1%. Six-year PFS and OS were significantly higher after bone marrow transplantation compared to HCT from other sources, whereas NRM was significantly lower. This pioneering multicentric study examining allogeneic HCT outcomes in children with myelofibrosis demonstrated both the feasibility and curative potential of this procedure, while highlighting the need for further investigation<sup>46</sup>.

## CONFLICT OF INTEREST

Nothing to declare.

## DATA AVAILABILITY STATEMENT

Data sharing is not applicable.

## AUTHORS' CONTRIBUTIONS

**Substantive scientific and intellectual contributions to the study:** Villela NC, Oliveira AF, Ferreira RS, Zamperlini G, Bassani ACF, Michalowski MB and Lee MLM. **Conception and design:** Villela NC and Oliveira AF. **Manuscript writing:** Villela NC, Oliveira AF, Ferreira RS, Zamperlini G, Bassani ACF, Michalowski MB and Lee MLM. **Final approval:** Villela NC and Oliveira AF.

## FUNDING

Not applicable.

## ACKNOWLEDGEMENTS

Not applicable.

## REFERENCES

1. Aricó M, Biondi A, Pui C-H. Juvenile myelomonocytic leukemia. *Blood*. 1997;90(2):479–88.
2. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. *Blood J*. 2015;125(7):1083–90. <https://doi.org/10.1182/blood-2014-08-550483>
3. Hasle H, Niemeyer C, Chessells J, Baumann I, Bennett JM, Kerndrup G, Head DR. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. *Leukemia*. 2003;17(2):277–82. <https://doi.org/10.1038/sj.leu.2402765>
4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391–405. <https://doi.org/10.1182/blood-2016-03-643544>
5. Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. *Virchows Arch*. 2023;482(1):113–30. <https://doi.org/10.1007/s00428-022-03447-9>
6. Locatelli F, Algeri M, Merli P, Strocchio L. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. *Expert Rev Hematol*. 2018;11(2):129–43. <https://doi.org/10.1080/17474086.2018.1421937>
7. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH Jr, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber T, Golub T, Stegmaier K, Loh ML. The genomic landscape of juvenile myelomonocytic leukemia. *Nat Genet*. 2015;47(11):1326–33. <https://doi.org/10.1038/ng.3400>
8. Wintering A, Dvorak CC, Stieglitz E, Loh ML. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. *Blood Adv*. 2021;5(22):4783–93. <https://doi.org/10.1182/bloodadvances.2021005117>
9. Mayerhofer C, Niemeyer CM, Flotho C. Current treatment of juvenile myelomonocytic leukemia. *J Clin Med*. 2021;10(14):3084. <https://doi.org/10.3390/jcm10143084>
10. Schönung M, Meyer J, Nöllke P, Olshen AB, Hartmann M, Murakami N, Wakamatsu M, Okuno Y, Plass C, Loh ML, Niemeyer CM, Muramatsu H, Flotho C, Stieglitz E, Lipka DB. International Consensus Definition of DNA methylation subgroups in juvenile myelomonocytic leukemia. *Clin Cancer Res*. 2021;27(1):158–68. <https://doi.org/10.1158/1078-0432.ccr-20-3184>
11. Bergstraesser E, Hasle H, Rogge T, Fischer A, Zimmermann M, Noellke P, Niemeyer CM. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. *Pediatr Blood Cancer*. 2007;49(5):629–33. <https://doi.org/10.1002/pbc.21038>
12. Hecht A, Meyer J, Chehab FF, White KL, Magruder K, Dvorak CC, Loh ML, Stieglitz E. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. *Pediatr Blood Cancer*. 2019;66(11):e27948. <https://doi.org/10.1002/pbc.27948>
13. Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, Niemeyer CM. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. *Blood*. 2009;113(12):2867–8. <https://doi.org/10.1182/blood-2008-12-195693>

14. Cseh A, Niemeyer CM, Yoshimi A, Dworzak M, Hasle H, van den Heuvel-Eibrink MM, Locatelli F, Masetti R, Schmugge M, Groß-Wieltsch U, Candás A, Kulozik AE, Olcay L, Suttorp M, Furlan I, Strahm B, Flotho C. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. *Blood*. 2015;125(14):2311–3. <https://doi.org/10.1182/blood-2015-01-619734>
15. Krombholz CF, Gallego-Villar L, Sahoo SS, Panda PK, Wlodarski MW, Aumann K, Hartmann M, Lipka DB, Daskalakis M, Plass C, Niemeyer CM, Erlacher M, Flotho C. Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia. *Leukemia*. 2019;33(7):1805–10. <https://doi.org/10.1038/s41375-018-0343-2>
16. Cai Y, Zhang J, Yi M, Zhang W, Liu X, Zhang X, Wan Y, Chang L, Zhang L, Chen X, Guo Y, Zou Y, Chen Y, Li J, Zhang Y, Yang W, Zhu X. Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China. *Int J Hematol*. 2023;117(1):121–7. <https://doi.org/10.1007/s12185-022-03457-y>
17. Peng Z, Gao J, Huang L, He Y, Tang H, Zong S, Pei Y, Pei F, Ge J, Liu X, Yue L, Zhou J, Li X, Yue D, Chen Y, Chen C, Wu X, Feng X, Li C. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study. *Front Immunol*. 2024;15:1426640. <https://doi.org/10.3389/fimmu.2024.1426640>
18. Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. *Blood Adv*. 2021;5(14):2901–8. <https://doi.org/10.1182/bloodadvances.2020004144>
19. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. *Br J Haematol*. 2011;152(6):677–87. <https://doi.org/10.1111/j.1365-2141.2010.08525.x>
20. Niemeyer CM. JMML genomics and decisions. *Hematology Am Soc Hematol Educ Program*. 2018;2018(1):307–12. <https://doi.org/10.1182/asheducation-2018.1.307>
21. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz E. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. *Haematologica*. 2022;107(1):178–86. <https://doi.org/10.3324/haematol.2020.270595>
22. Yoshida T, Muramatsu H, Wakamatsu M, Sajiki D, Murakami N, Kitazawa H, Okamoto Y, Taniguchi R, Kataoka S, Narita A, Hama A, Okuno Y, Takahashi Y. Clinical and molecular features of CBL-mutated juvenile myelomonocytic leukemia. *Haematologica*. 2023;108(11):3115–9. <https://doi.org/10.3324/haematol.2022.282385>
23. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Révész T, Führer M, Hasle H, Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, Niemeyer CM; European Working Group on Childhood MDS; European Blood and Marrow Transplantation Group. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. *Blood*. 2005;105(1):410–9. <https://doi.org/10.1182/blood-2004-05-1944>
24. Sakashita K, Yoshida N, Muramatsu H, Ohtsuka Y, Watanabe K, Yabe M, Kakuda H, Honda Y, Watanabe T, Haba M, Ohmori S, Matsuda K, Yuza Y, Saito A, Horibe K, Adachi S, Manabe A. Allogeneic hematopoietic cell transplantation for juvenile myelomonocytic leukemia with a busulfan, fludarabine, and melphalan regimen: JPLSG JMML-11. *Transplant Cell Ther*. 2024;30(1):105.e1–e10. <https://doi.org/10.1016/j.jtct.2023.10.002>

25. Smith FO, King R, Nelson G, Wagner JE, Robertson KA, Sanders JE, Bunin N, Emanuel PD, Davies SM; National Marrow Donor Program. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. *Br J Haematol*. 2002;116(3):716–24. <https://doi.org/10.1046/j.0007-1048.2001.03333.x>
26. Locatelli F, Crotta A, Ruggeri A, Eapen M, Wagner JE, Macmillan ML, Zecca M, Kurtzberg J, Bonfim C, Vora A, Díaz de Heredia C, Teague L, Stein J, O'Brien TA, Bittencourt H, Madureira A, Strahm B, Peters C, Niemeyer C, Gluckman E, Rocha V. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. *Blood*. 2013;122(12):2135–41. <https://doi.org/10.1182/blood-2013-03-491589>
27. Kalwak K, Wójcik D, Gorczyńska E, Toporski J, Turkiewicz D, Słociak M, Ussowicz M, Pajdosz K, Socha P, Chybicka A. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative? *Transplant Proc*. 2004;36(5):1574–7. <https://doi.org/10.1016/j.transproceed.2004.05.081>
28. Trujillo ÁM, Karduss AJ, Suarez G, Pérez R, Ruiz G, Cardona A, Ramírez M, Betancur J. Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source. *Transplant Cell Ther*. 2021;27(5):427.e1–e7. <https://doi.org/10.1016/j.jtct.2021.02.010>
29. Ding L, Zhu H, Han DM, Wang ZD, Zheng XL, Dong L, Yan HM, Liu J, Zhu L, Xue M, Guo ZK, Wang HX. [Clinical study on treatment of juvenile myelomonocytic leukemia with haploidentical-hematopoietic stem cell transplantation]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2017;25(5):1524–7. <https://doi.org/10.7534/j.issn.1009-2137.2017.05.043>
30. Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. *Pediatr Blood Cancer*. 2018;65(7):e27034. <https://doi.org/10.1002/pbc.27034>
31. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA, Pötschger U, Gadner H. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. *Bone Marrow Transplant*. 2000;26(4):377–82. <https://doi.org/10.1038/sj.bmt.1702522>
32. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H, Kojima S, Koike K, Saito T, Nakahata T; MDS Committee of the Japanese Society of Pediatric Hematology. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. *Leukemia*. 2002;16(4):645–9. <https://doi.org/10.1038/sj.leu.2402407>
33. Matthes-Martin S, Mann G, Peters C, Lion T, Fritsch G, Haas OA, Pötschger U, Gadner H. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. *Bone Marrow Transplant*. 2000;26(4):377–82. <https://doi.org/10.1038/sj.bmt.1702522>
34. Vinci L, Flotho C, Noellke P, Lebrecht D, Masetti R, de Haas V, De Moerloose B, Dworzak M, Hasle H, Gungör T, Starý J, Turkiewicz D, Ussowicz M, de Heredia CD, Buechner J, Jahnukainen K, Kallay K, Bodova I, Smith OP, Zecca M, Bresters D, Lang P, Masmans TN, Meisel R, Pichler H, Erlacher M, Göhring G, Locatelli F, Strahm B, Niemeyer CM, Yoshimi A. Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft. *Bone Marrow Transplant*. 2023;58(5):607–9. <https://doi.org/10.1038/s41409-023-01942-4>
35. Chang Y-H, Jou S-T, Lin D-T, Lu M-Y, Lin K-H. Second allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: case report and literature review. *J Pediatr Hematol Oncol*. 2004;26(3):190–3. <https://doi.org/10.1097/00043426-200403000-00009>

36. Meyran D, Arfeuille C, Chevret S, Neven Q, Caye-Eude A, Lainey E, Petit A, Rialland F, Michel G, Plantaz D, Jubert C, Theron A, Gandemer V, Ouachée-Chardin M, Paillard C, Bruno B, Buchbinder N, Pochon C, Calvo C, Fahd M, Baruchel A, Cavé H, Dalle JH, Strullu M. A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. *Haematologica*. 2024;109(9):2908–19. <https://doi.org/10.3324/haematol.2023.284103>
37. Yoshimi A, Niemeyer CM, Bohmer V, Duffner U, Strahm B, Kreyenberg H, Dilloo D, Zintl F, Claviez A, Wössmann W, Kremens B, Holter W, Niethammer D, Beck JF, Kontny U, Nöllke P, Klingebiel T, Bader P. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. *Br J Haematol*. 2005;129(4):542–9. <https://doi.org/10.1111/j.1365-2141.2005.05489.x>
38. Inagaki J, Fukano R, Nishikawa T, Nakashima K, Sawa D, Ito N, Okamura J. Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. *Pediatr Blood Cancer*. 2013;60(1):116–20. <https://doi.org/10.1002/pbc.24259>
39. Stieglitz E, Lee AG, Angus SP, Davis C, Barkauskas DA, Hall D, Kogan SC, Meyer J, Rhodes SD, Tasian SK, Xuei X, Shannon K, Loh ML, Fox E, Weigel BJ. Efficacy of the allosteric MEK inhibitor trametinib in relapsed and refractory juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. *Cancer Discov*. 2024;14(9):1590–8. <https://doi.org/10.1158/2159-8290.CD-23-1376>
40. Hofmann I. Myeloproliferative neoplasms in children. *J Hematop*. 2015;8(3):143–57. <https://doi.org/10.1007/s12308-015-0256-1>
41. Kucine N. Myeloproliferative neoplasms in children, adolescents, and young adults. *Curr Hematol Malig Rep*. 2020;15(2):141–8. <https://doi.org/10.1007/s11899-020-00571-8>
42. Sobas M, Ianotto JC, Kiladjian JJ, Harrison C. Myeloproliferative neoplasms: young patients, current data and future considerations. *Ann Hematol*. 2024;103(9):3287–91. <https://doi.org/10.1007/s00277-024-05920-8>
43. Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrengeha M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. *Blood Adv*. 2022;6(17):5171–83. <https://doi.org/10.1182/bloodadvances.2022007201>
44. Wachowiak J, Galimard JE, Dalissier A, Rihani R, AlSaedi H, Wynn RF, Dalle JH, Peffault de Latour R, Sedlacek P, Balduzzi A, Schroeder T, Bodova I, Gonzalez Vicent M, Gruhn B, Hamladji RM, Krivan G, Patrick K, Sobkowiak-Sobierajska A, Stepensky P, Unal A, Amrolia P, Perez Martinez A, Rialland F, Aljurf M, Isgro A, Toren A, Bierings M, Corbacioglu S, Kałwak K. Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP. *Bone Marrow Transplant*. 2024;59(8):1057–69. <https://doi.org/10.1038/s41409-024-02286-3>
45. Putti MC, Bertozzi I, Randi ML. Essential thrombocythemia in children and adolescents. *Cancers (Basel)*. 2021;13(23):6147. <https://doi.org/10.3390/cancers13236147>
46. Picard A, Bayart S, Deparis M, De Maricourt CD, Haro S, Jourdain A, Mallebranche C, Rialland F, Luque Paz D, Pastoret C, Gandemer V, Cousin E. Polycythemia vera and essential thrombocythemia in children, still a challenge for pediatricians. *Eur J Pediatr*. 2025;184(2):173. <https://doi.org/10.1007/s00431-025-05993-1>